Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBIT Margin (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBIT Margin for 10 consecutive years, with 15.02% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 5370.0% year-over-year to 15.02%, compared with a TTM value of 1.32% through Dec 2025, up 19636.0%, and an annual FY2025 reading of 1.17%, up 12476.0% over the prior year.
  • EBIT Margin was 15.02% for Q4 2025 at Anaptysbio, down from 69.41% in the prior quarter.
  • Across five years, EBIT Margin topped out at 69.41% in Q3 2025 and bottomed at 3273.09% in Q1 2022.
  • Average EBIT Margin over 5 years is 947.49%, with a median of 417.72% recorded in 2023.
  • The sharpest move saw EBIT Margin tumbled -312944bps in 2021, then surged 264367bps in 2024.
  • Year by year, EBIT Margin stood at 3081.8% in 2021, then soared by 83bps to 519.46% in 2022, then rose by 10bps to 467.91% in 2023, then skyrocketed by 92bps to 38.68% in 2024, then skyrocketed by 139bps to 15.02% in 2025.
  • Business Quant data shows EBIT Margin for ANAB at 15.02% in Q4 2025, 69.41% in Q3 2025, and 117.55% in Q2 2025.